Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLTO Galecto	$3.75 -1.3%	$3.36	$2.01 ▼ $15.13	$5.03M	1.35	25,750 shs	4,316 shs
IXHL Incannex Healthcare	$1.05 -35.6%	$0.32	$0.08 ▼ $3.12	$47.98M	7.47	152.22 million shs	218.88 million shs
LEXX Lexaria Bioscience	$0.98 -3.2%	$0.95	$0.79 ▼ $4.38	$19.75M	0.79	130,171 shs	197,103 shs
RLYB Rallybio	$0.50 -4.8%	$0.37	$0.22 ▼ $1.54	$21.81M	-1.17	8.35 million shs	292,773 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLTO Galecto	+1.18%	+5.34%	+13.09%	+32.59%	-72.29%
IXHL Incannex Healthcare	+61.39%	+340.42%	+640.91%	+180.55%	-23.47%
LEXX Lexaria Bioscience	-1.94%	+16.09%	+6.32%	-25.19%	-67.83%
RLYB Rallybio	-0.95%	+15.24%	+41.62%	+72.77%	-59.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GLTO Galecto	3.7295 of 5 stars	3.5	5.0	3.3	1.7	1.3
IXHL Incannex Healthcare	0.7355 of 5 stars	0.0	4.0	2.9	0.8	0.0
LEXX Lexaria Bioscience	2.2459 of 5 stars	3.5	2.0	2.0	1.7	0.6
RLYB Rallybio	2.879 of 5 stars	3.0	3.0	3.3	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLTO Galecto	3.00	Buy	$10.00	166.67% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
LEXX Lexaria Bioscience	3.00	Buy	$5.00	411.25% Upside
RLYB Rallybio	2.00	Hold	$10.00	1,905.21% Upside

Current Analyst Ratings Breakdown

Latest GLTO, LEXX, IXHL, and RLYB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/1/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLTO Galecto	N/A	N/A	N/A	N/A	$10.99 per share	N/A
IXHL Incannex Healthcare	$10K	3,090.15	N/A	N/A	$0.18 per share	5.83
LEXX Lexaria Bioscience	$460K	41.59	N/A	N/A	$0.26 per share	3.76
RLYB Rallybio	$640K	32.42	N/A	N/A	$1.49 per share	0.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLTO Galecto	-$21.44M	-$15.53	N/A	N/A	N/A	N/A	-98.27%	-84.29%	8/11/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)
LEXX Lexaria Bioscience	-$5.80M	-$0.67	N/A	N/A	N/A	-1,849.19%	-157.22%	-133.69%	N/A
RLYB Rallybio	-$57.78M	-$1.09	N/A	N/A	N/A	-5,682.19%	-72.31%	-64.78%	8/14/2025 (Estimated)

Latest GLTO, LEXX, IXHL, and RLYB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/14/2025	Q3 2025	LEXX Lexaria Bioscience	-$0.15	-$0.21	-$0.06	-$0.21	$0.17 million	$0.17 million
5/15/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	-$0.24	+$0.22	-$0.20	$0.16 million	$0.10 million
5/8/2025	Q1 2025	GLTO Galecto	N/A	-$1.92	N/A	-$1.92	N/A	N/A
5/8/2025	Q1 2025	RLYB Rallybio	-$0.21	-$0.21	N/A	-$0.21	N/A	$0.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLTO Galecto	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLTO Galecto	N/A	9.62	9.62
IXHL Incannex Healthcare	N/A	2.12	2.12
LEXX Lexaria Bioscience	N/A	3.90	3.90
RLYB Rallybio	N/A	14.68	14.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLTO Galecto	14.20%
IXHL Incannex Healthcare	0.43%
LEXX Lexaria Bioscience	13.06%
RLYB Rallybio	90.34%

Insider Ownership

Company	Insider Ownership
GLTO Galecto	10.80%
IXHL Incannex Healthcare	15.49%
LEXX Lexaria Bioscience	26.40%
RLYB Rallybio	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLTO Galecto	40	1.32 million	1.18 million	Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
LEXX Lexaria Bioscience	7	19.56 million	14.40 million	Not Optionable
RLYB Rallybio	40	41.61 million	37.99 million	Not Optionable

GLTO, LEXX, IXHL, and RLYB Headlines

Recent News About These Companies

Rallybio (NASDAQ:RLYB) Shares Up 4.4% - Should You Buy?

July 17, 2025 | americanbankingnews.com

Evercore ISI Remains a Hold on Rallybio (RLYB)

July 16, 2025 | theglobeandmail.com

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia ... - Nasdaq

July 11, 2025 | nasdaq.com

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - Morningstar

July 9, 2025 | morningstar.comM

Here's Why Shares in Recursion Pharmaceuticals Surged Today

July 8, 2025 | finance.yahoo.com

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

July 8, 2025 | finance.yahoo.com

Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug

July 8, 2025 | msn.com

Rallybio Sells REV102 Program to Recursion Pharmaceuticals

July 8, 2025 | tipranks.com

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

June 13, 2025 | finance.yahoo.com

Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook

May 24, 2025 | investing.com

Rallybio shareholders elect directors, ratify auditor

May 18, 2025 | uk.investing.com

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finance.yahoo.com

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

April 29, 2025 | finance.yahoo.com

Jones Trading Downgrades Rallybio (RLYB)

April 15, 2025 | msn.com

Rallybio downgraded to Hold from Buy at JonesResearch

April 14, 2025 | markets.businessinsider.com

Rallybio downgraded to In Line from Outperform at Evercore ISI

April 11, 2025 | markets.businessinsider.com

Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright

April 10, 2025 | markets.businessinsider.com

Rallybio Stock Short Interest Report | NASDAQ:RLYB | Benzinga

April 9, 2025 | benzinga.com

Rallybio discontinues RLYB212 program

April 9, 2025 | markets.businessinsider.com

Rallybio sinks as it drops RLYB212 for prevention of FNAIT

April 9, 2025 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLTO, LEXX, IXHL, and RLYB Company Descriptions

Galecto NASDAQ:GLTO

$3.81 +0.01 (+0.26%)

As of 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Incannex Healthcare NASDAQ:IXHL

$1.05 -0.58 (-35.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.10 +0.05 (+5.24%)

As of 08:00 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Lexaria Bioscience NASDAQ:LEXX

$0.98 -0.03 (-3.17%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 +0.00 (+0.20%)

As of 07:59 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Rallybio NASDAQ:RLYB

$0.50 -0.03 (-4.83%)

Closing price 04:00 PM Eastern

Extended Trading

$0.51 +0.01 (+1.86%)

As of 07:58 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time